Cargando…
Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer
BACKGROUND: Salvage endoscopic therapy (SET), such as endoscopic mucosal resection (EMR) and photodynamic therapy (PDT), is a less-invasive treatment for local failure at the primary site after chemoradiotherapy (CRT) for esophageal squamous cell carcinoma (ESCC). We conducted this retrospective stu...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769588/ https://www.ncbi.nlm.nih.gov/pubmed/26922374 http://dx.doi.org/10.1186/s13014-016-0604-z |
_version_ | 1782418131154632704 |
---|---|
author | Hatogai, Ken Yano, Tomonori Kojima, Takashi Onozawa, Masakatsu Fujii, Satoshi Daiko, Hiroyuki Yoda, Yusuke Hombu, Takuya Doi, Toshihiko Kaneko, Kazuhiro Ohtsu, Atsushi |
author_facet | Hatogai, Ken Yano, Tomonori Kojima, Takashi Onozawa, Masakatsu Fujii, Satoshi Daiko, Hiroyuki Yoda, Yusuke Hombu, Takuya Doi, Toshihiko Kaneko, Kazuhiro Ohtsu, Atsushi |
author_sort | Hatogai, Ken |
collection | PubMed |
description | BACKGROUND: Salvage endoscopic therapy (SET), such as endoscopic mucosal resection (EMR) and photodynamic therapy (PDT), is a less-invasive treatment for local failure at the primary site after chemoradiotherapy (CRT) for esophageal squamous cell carcinoma (ESCC). We conducted this retrospective study to clarify the risk factors for local recurrence along with the long term results after SET for recurrent lesions after definitive CRT for ESCC. METHODS: We enrolled 77 consecutive patients who underwent EMR or PDT for local recurrence without any metastasis after definitive CRT at our institution. We evaluated the local efficacy, local recurrence-free survival (LRFS), and overall survival (OS), and investigated the risk factors associated with survival outcome using a multivariate analysis. RESULTS: The complete resection rate of EMR was 84.6 % (33/39), and the complete response rate for PDT was 65.8 % (25/38). Twenty-two patients (28.6 %) exhibited local recurrence without metastasis. Thirty-four patients (44.2 %) were alive at 5 years after undergoing only initial SET or with repeated SET. The 5-year LRFS rate was 59.6 %, and the presence of lesions occupying an esophageal circumference of 1/4 or larger was the only significant risk factor (HR: 3.10, 95 % CI: 1.35–7.15, P = 0.008). The 5-year OS rate was 48.4 %, and an advanced T factor before CRT was marginally associated with a poor OS (HR: 1.96, 95 % CI: 0.98–3.92, P = 0.055). CONCLUSIONS: SET enabled a preferable local control and survival outcome for patients with local recurrence after definitive CRT for ESCC. Careful endoscopic follow-up is needed for patients with a large lesion before SET and those with an advanced T factor before CRT. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13014-016-0604-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4769588 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47695882016-02-28 Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer Hatogai, Ken Yano, Tomonori Kojima, Takashi Onozawa, Masakatsu Fujii, Satoshi Daiko, Hiroyuki Yoda, Yusuke Hombu, Takuya Doi, Toshihiko Kaneko, Kazuhiro Ohtsu, Atsushi Radiat Oncol Research BACKGROUND: Salvage endoscopic therapy (SET), such as endoscopic mucosal resection (EMR) and photodynamic therapy (PDT), is a less-invasive treatment for local failure at the primary site after chemoradiotherapy (CRT) for esophageal squamous cell carcinoma (ESCC). We conducted this retrospective study to clarify the risk factors for local recurrence along with the long term results after SET for recurrent lesions after definitive CRT for ESCC. METHODS: We enrolled 77 consecutive patients who underwent EMR or PDT for local recurrence without any metastasis after definitive CRT at our institution. We evaluated the local efficacy, local recurrence-free survival (LRFS), and overall survival (OS), and investigated the risk factors associated with survival outcome using a multivariate analysis. RESULTS: The complete resection rate of EMR was 84.6 % (33/39), and the complete response rate for PDT was 65.8 % (25/38). Twenty-two patients (28.6 %) exhibited local recurrence without metastasis. Thirty-four patients (44.2 %) were alive at 5 years after undergoing only initial SET or with repeated SET. The 5-year LRFS rate was 59.6 %, and the presence of lesions occupying an esophageal circumference of 1/4 or larger was the only significant risk factor (HR: 3.10, 95 % CI: 1.35–7.15, P = 0.008). The 5-year OS rate was 48.4 %, and an advanced T factor before CRT was marginally associated with a poor OS (HR: 1.96, 95 % CI: 0.98–3.92, P = 0.055). CONCLUSIONS: SET enabled a preferable local control and survival outcome for patients with local recurrence after definitive CRT for ESCC. Careful endoscopic follow-up is needed for patients with a large lesion before SET and those with an advanced T factor before CRT. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13014-016-0604-z) contains supplementary material, which is available to authorized users. BioMed Central 2016-02-27 /pmc/articles/PMC4769588/ /pubmed/26922374 http://dx.doi.org/10.1186/s13014-016-0604-z Text en © Hatogai et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Hatogai, Ken Yano, Tomonori Kojima, Takashi Onozawa, Masakatsu Fujii, Satoshi Daiko, Hiroyuki Yoda, Yusuke Hombu, Takuya Doi, Toshihiko Kaneko, Kazuhiro Ohtsu, Atsushi Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer |
title | Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer |
title_full | Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer |
title_fullStr | Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer |
title_full_unstemmed | Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer |
title_short | Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer |
title_sort | local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769588/ https://www.ncbi.nlm.nih.gov/pubmed/26922374 http://dx.doi.org/10.1186/s13014-016-0604-z |
work_keys_str_mv | AT hatogaiken localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer AT yanotomonori localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer AT kojimatakashi localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer AT onozawamasakatsu localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer AT fujiisatoshi localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer AT daikohiroyuki localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer AT yodayusuke localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer AT hombutakuya localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer AT doitoshihiko localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer AT kanekokazuhiro localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer AT ohtsuatsushi localefficacyandsurvivaloutcomeofsalvageendoscopictherapyforlocalrecurrentlesionsafterdefinitivechemoradiotherapyforesophagealcancer |